Investigator Centers Will Be All French Hematology Centers Performing Autologous Transplantation and Prescribing Mozobil in Hematopoietic Stem Cell Mobilization Willing to Participate In This Study

Genzyme, a Sanofi Company0 sites262 target enrollmentDecember 2011

ConditionsBone Marrow / Autologous Transplants

DrugsPlerixafor

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Bone Marrow / Autologous Transplants
Sponsor: Genzyme, a Sanofi Company
Enrollment: 262
Primary Endpoint: Duration of treatment
Status: Completed
Last Updated: 11 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

The aim of this registry is to provide information, in day-to-day practice, on Plerixafor prescription modalities in France, over a 13-month period in order to address the health authorities' request.

Registry

clinicaltrials.gov

Start Date

December 2011

End Date

November 2012

Last Updated

11 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Genzyme, a Sanofi Company

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients treated with Plerixafor for autologous transplantation between November 2011 and November 2012
•Patients who have been informed and who have given their written consent for the access to their medical file